In schizophrenia, speech production deficits in patients with positive formal thought disorder (FTD e.g. loosening of associations and derailment) have been attributed to impairments in the semantic network. The brain area implicated in the retrieval of associated (i.e. relational) concepts is the hippocampus, a key region in the psychopathology of schizophrenia. However, its role in schizophrenic speech production and FTD in particular is yet little understood. To investigate the neural correlates of associative verbal retrieval, twelve patients with schizophrenia with varying degrees of FTD and twelve matched healthy control subjects underwent a free verbal association (FVA), a semantic (SVF) and a phonological verbal fluency (PVF) task while brain activity was measured with fMRI. The tasks varied in the relational binding operations needed for linking the stimulus to the respective response. Compared to control subjects, patients revealed attenuated left hippocampal activity during both semantic word generation tasks (FVA, SVF). Contrasting verbal fluency with FVA, a failure in recruiting the anterior cingulate gyrus emerged in the patient group. A negative correlation was found between right middle temporal activity and the severity of FTD during FVA. The hippocampus seems to play a major role in word generation. In schizophrenia, attenuated hippocampal activity during semantic tasks strengthens the hypothesis of impaired relational memory processes, affecting thought and language.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.schres.2008.02.003DOI Listing

Publication Analysis

Top Keywords

patients schizophrenia
8
speech production
8
control subjects
8
verbal fluency
8
hippocampal activity
8
activity semantic
8
word generation
8
schizophrenia
5
hippocampal dysfunction
4
dysfunction free
4

Similar Publications

Schizophrenia (SZ) is a chronic neuropsychiatric disorder characterized by disturbances in cognitive, perceptual, social, emotional, and behavioral functions. The conventional SZ diagnosis relies on subjective assessments of individuals by psychiatrists, which can result in bias, prolonged procedures, and potentially false diagnoses. This emphasizes the crucial need for early detection and treatment of SZ to provide timely support and minimize long-term impacts.

View Article and Find Full Text PDF

Efficacy of Lurasidone in First-Episode Psychosis: Patient Phenotypes, Dosage, and Recommendations from an Expert Panel.

Neurol Ther

January 2025

Department of Psychiatry, Faculty of Medicine, Mental Health Unit, Virgen del Rocio University Hospital, Translational Psychiatry Group, IBiS-CSIC, CIBERSAM, University of Seville, Seville, Spain.

Introduction: For patients with psychosis, early, intensive therapeutic intervention is thought to improve long-term outcomes. Furthermore, patients with a first-episode psychosis (FEP) who experience a good early response to antipsychotic medication show a clinical and functional benefit over the longer term if they continue low-dose antipsychotic treatment. Lurasidone is an atypical antipsychotic agent which is approved in Europe for the treatment of schizophrenia in adults and adolescents (13-17 years).

View Article and Find Full Text PDF

Transdiagnostic conceptualization of schizophrenia and autism spectrum disorder. An integrative framework of minimal self disturbance.

Neuropsychopharmacol Hung

December 2024

Pszichiátriai és Pszichoterápiás Klinika, Semmelweis Egyetem, Budapest.

Aims: Autism spectrum disorder and schizophrenia are traditionally viewed as distinct diagnostic categories. However, evidence increasingly suggests overlapping pathological functioning at various levels, starting from brain circuitry to behaviour. Notably, both disorders are characterized by anomalous minimal self-experience (altered body ownership and agency), which is a trait-like, phenomenological distortion.

View Article and Find Full Text PDF

Efficacy and safety of iclepertin (BI 425809) with adjunctive computerized cognitive training in patients with schizophrenia.

Schizophr Res Cogn

June 2025

Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, CT 06877, USA.

Unlabelled: Despite significant patient burden, there are no approved pharmacotherapies to treat symptoms of cognitive impairment associated with schizophrenia (CIAS). This double-blind, placebo-controlled, parallel-group Phase II trial assessed the efficacy and safety of pharmacological augmentation of at-home computerized cognitive training (CCT) with iclepertin (BI 425809, a glycine transporter-1 inhibitor). Participants with schizophrenia (aged 18-50 years) on stable antipsychotic therapy, who were compliant with CCT during the run-in period, were enrolled.

View Article and Find Full Text PDF

Advances in transcranial focused ultrasound neuromodulation for mental disorders.

Prog Neuropsychopharmacol Biol Psychiatry

January 2025

Department of Rehabilitation, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China. Electronic address:

Mental disorders are a major public health concern, affecting millions worldwide. Current treatments have limitations, highlighting the need for novel, effective, and safe interventions. Transcranial focused ultrasound (tFUS), a non-invasive neuromodulation technology, has emerged as a promising tool for treating mental disorders due to its high controllability, precision, and safety.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!